{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:35:30Z","timestamp":1790775330364,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The purposes of the present study were to identify anti-striational antibodies in myasthenia gravis (MG) patients with myositis and\/or myocarditis using a combination of cell-based assays and flow cytometry (cytometric cell-based assays) and to describe the main clinical implications. Among 2,609 stored samples collected from all over Japan between 2003 and 2016, we had serum samples from 30 MG patients with myositis and\/or myocarditis. Cytometric cell-based assays with titin, ryanodine receptor, and voltage-gated Kv1.4 were performed. Autoantibodies were determined by differences in phycoerythin fluorescence between the 293F cells and titin-transfected cells. MG patients with myositis and\/or myocarditis as well as late-onset and thymoma-associated MG had anti-titin, anti-ryanodine receptor, and anti-Kv1.4 antibodies. In contrast, patients with early-onset MG, those with other myopathies and healthy controls did not have anti-titin or anti-Kv1.4 antibodies with some exceptions, but they possessed anti-ryanodine receptor antibodies. Thirty MG patients with myositis and\/or myocarditis showed a severe generalized form, and 21 of them had thymoma. Anti-titin and anti-Kv1.4 antibodies were found in 28 (93%) and 15 (50%) patients, respectively, and all patients had at least one of these antibodies. Cytometric cell-based assays thus demonstrated that anti-striational antibodies are biomarkers of MG with myositis and\/or myocarditis.<\/jats:p>","DOI":"10.1038\/s41598-019-41730-z","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T16:49:55Z","timestamp":1553705395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and\/or myocarditis"],"prefix":"10.1038","volume":"9","author":[{"given":"Kenji","family":"Kufukihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutaro","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1958-095X","authenticated-orcid":false,"given":"Shunya","family":"Nakane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"key":"41730_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0140-6736(66)92356-7","volume":"1","author":"HW van der Geld","year":"1966","unstructured":"van der Geld, H. W. & Strauss, A. J. Myasthenia gravis. Immunological relationship between striated muscle and thymus. Lancet 1, 57\u201360 (1966).","journal-title":"Lancet"},{"key":"41730_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1365-2249.1990.tb05440.x","volume":"82","author":"JA Aarli","year":"1990","unstructured":"Aarli, J. A., Stefansson, K., Marton, L. S. & Wollmann, R. L. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 82, 284\u2013288 (1990).","journal-title":"Clin Exp Immunol"},{"key":"41730_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ana.410320419","volume":"32","author":"A Mygland","year":"1992","unstructured":"Mygland, A. et al. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol 32, 589\u2013591, https:\/\/doi.org\/10.1002\/ana.410320419 (1992).","journal-title":"Ann Neurol"},{"key":"41730_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jneuroim.2005.08.017","volume":"170","author":"S Suzuki","year":"2005","unstructured":"Suzuki, S. et al. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol 170, 141\u2013149, https:\/\/doi.org\/10.1016\/j.jneuroim.2005.08.017 (2005).","journal-title":"J Neuroimmunol"},{"key":"41730_CR5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/archneur.57.4.527","volume":"57","author":"A Mygland","year":"2000","unstructured":"Mygland, A. et al. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol 57, 527\u2013531 (2000).","journal-title":"Arch Neurol"},{"key":"41730_CR6","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","volume":"66","author":"S Suzuki","year":"2009","unstructured":"Suzuki, S. et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 66, 1334\u20131338, https:\/\/doi.org\/10.1001\/archneurol.2009.229 (2009).","journal-title":"Arch Neurol"},{"key":"41730_CR7","doi-asserted-by":"publisher","unstructured":"Waters, P. J. et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78, 665\u2013671; discussion 669, https:\/\/doi.org\/10.1212\/WNL.0b013e318248dec1 (2012).","DOI":"10.1212\/WNL.0b013e318248dec1"},{"key":"41730_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1708712","volume":"378","author":"J Dalmau","year":"2018","unstructured":"Dalmau, J. & Graus, F. Antibody-Mediated Encephalitis. N Engl J Med 378, 840\u2013851, https:\/\/doi.org\/10.1056\/NEJMra1708712 (2018).","journal-title":"N Engl J Med"},{"key":"41730_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","volume":"52","author":"P Zisimopoulou","year":"2014","unstructured":"Zisimopoulou, P. et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52, 139\u2013145, https:\/\/doi.org\/10.1016\/j.jaut.2013.12.004 (2014).","journal-title":"J Autoimmun"},{"key":"41730_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/ene.12234","volume":"21","author":"S Suzuki","year":"2014","unstructured":"Suzuki, S. et al. Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur J Neurol 21, 223\u2013230, https:\/\/doi.org\/10.1111\/ene.12234 (2014).","journal-title":"Eur J Neurol"},{"key":"41730_CR11","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1212\/WNL.43.8.1581","volume":"43","author":"M Gautel","year":"1993","unstructured":"Gautel, M. et al. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 43, 1581\u20131585 (1993).","journal-title":"Neurology"},{"key":"41730_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/mus.10294","volume":"27","author":"GO Skeie","year":"2003","unstructured":"Skeie, G. O. et al. Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro. Muscle Nerve 27, 81\u201389, https:\/\/doi.org\/10.1002\/mus.10294 (2003).","journal-title":"Muscle Nerve"},{"key":"41730_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archneur.62.3.442","volume":"62","author":"F Romi","year":"2005","unstructured":"Romi, F., Skeie, G. O., Gilhus, N. E. & Aarli, J. A. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 62, 442\u2013446, https:\/\/doi.org\/10.1001\/archneur.62.3.442 (2005).","journal-title":"Arch Neurol"},{"key":"41730_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneuroim.2016.01.018","volume":"292","author":"C Stergiou","year":"2016","unstructured":"Stergiou, C. et al. Titin antibodies in \u201cseronegative\u201d myasthenia gravis\u2013A new role for an old antigen. J Neuroimmunol 292, 108\u2013115, https:\/\/doi.org\/10.1016\/j.jneuroim.2016.01.018 (2016).","journal-title":"J Neuroimmunol"},{"key":"41730_CR15","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.clinph.2011.10.038","volume":"123","author":"T Imai","year":"2012","unstructured":"Imai, T. et al. Contribution of anti-ryanodine receptor antibody to impairment of excitation-contraction coupling in myasthenia gravis. Clin Neurophysiol 123, 1242\u20131247, https:\/\/doi.org\/10.1016\/j.clinph.2011.10.038 (2012).","journal-title":"Clin Neurophysiol"},{"key":"41730_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2014.05.001","volume":"52","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin, S. Myasthenia Gravis: paradox versus paradigm in autoimmunity. J Autoimmun 52, 1\u201328, https:\/\/doi.org\/10.1016\/j.jaut.2014.05.001 (2014).","journal-title":"J Autoimmun"},{"key":"41730_CR17","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.autrev.2017.04.009","volume":"16","author":"E Santos","year":"2017","unstructured":"Santos, E. et al. Inflammatory myopathy associated with myasthenia gravis with and without thymic pathology: Report of four cases and literature review. Autoimmun Rev 16, 644\u2013649, https:\/\/doi.org\/10.1016\/j.autrev.2017.04.009 (2017).","journal-title":"Autoimmun Rev"},{"key":"41730_CR18","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1212\/01.WNL.0000032502.89361.0C","volume":"59","author":"A Evoli","year":"2002","unstructured":"Evoli, A. et al. Thymoma in patients with MG: characteristics and long-term outcome. Neurology 59, 1844\u20131850 (2002).","journal-title":"Neurology"},{"key":"41730_CR19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/wnl.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki, S. et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89, 1127\u20131134, https:\/\/doi.org\/10.1212\/wnl.0000000000004359 (2017).","journal-title":"Neurology"},{"key":"41730_CR20","doi-asserted-by":"publisher","unstructured":"Brahmer, J. R. et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, JCO2017776385, https:\/\/doi.org\/10.1200\/jco.2017.77.6385 (2018).","DOI":"10.1200\/jco.2017.77.6385"},{"key":"41730_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jneuroim.2010.10.023","volume":"230","author":"S Suzuki","year":"2011","unstructured":"Suzuki, S. et al. Clinical and immunological differences between early and late-onset myasthenia gravis. J Neuroimmunol 230, 148\u2013152 (2011).","journal-title":"J Neuroimmunol"},{"key":"41730_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3109\/08916939409010673","volume":"17","author":"A Mygland","year":"1994","unstructured":"Mygland, A. et al. Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis. Autoimmunity 17, 327\u2013331 (1994).","journal-title":"Autoimmunity"},{"key":"41730_CR23","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1212\/01.WNL.0000125254.99397.68","volume":"62","author":"M Takamori","year":"2004","unstructured":"Takamori, M. et al. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 62, 1894\u20131896 (2004).","journal-title":"Neurology"},{"key":"41730_CR24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/s1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus, N. E. & Verschuuren, J. J. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14, 1023\u20131036, https:\/\/doi.org\/10.1016\/s1474-4422(15)00145-3 (2015).","journal-title":"Lancet Neurol"},{"key":"41730_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki III.","year":"2000","unstructured":"Jaretzki, A. 3rd et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55, 16\u201323 (2000).","journal-title":"Neurology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41730-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41730-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41730-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:16:53Z","timestamp":1671265013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41730-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["41730"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-41730-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"10 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5284"}}